


What is claimed is:

1. A polymer comprising a repeat unit of repeat unit of any one of Formulas (I) - (III),



wherein,

R¹, R², R³ and R⁴ are independently hydrogen or substituted or unsubstituted alkyl;

Y¹ in each occurrence is independently a direct bond or -L¹-A¹-L²-A²-;

L¹ in each occurrence is -NR⁹-, -NC(O)- or -C(O)N-;

L² in each occurrence is absent, -NR⁹-, -O- or -S-;

Y² in each occurrence is independently a direct bond or -L³-A¹-L²-A²-;


L³ in each occurrence is -C(O)- or absent;

L² in each occurrence is absent, -NR⁹-, -O- or -S-;

A¹ and A² in each occurrence are independently absent or optionally substituted C₁-C₅ alkylene;

R⁹, R¹⁰ and R¹¹ in each occurrence are independently hydrogen or substituted or unsubstituted alkyl (preferably a substituted or unsubstituted C₁-C₆ alkyl);

Z in each occurrence is



X^1 and X^2 are independently selected from a group consisting of hydrogen, halo, $-\text{CN}$, $-\text{NO}_2$, $-\text{N}^+(\text{R}^9)(\text{R}^{10})(\text{R}^{11})$, $-\text{CF}_3$, $-\text{SO}_3(\text{R}^9)$, $-\text{SO}_2(\text{R}^9)$, $-\text{CON}(\text{R}^9)(\text{R}^{10})$, $-(\text{CH}_2)_m-\text{N}(\text{R}^9)(\text{R}^{10})$, and $-\text{OR}^9$;

n is an integer from 1 to 100,000 and


m is an integer from 0 to 4;

with the proviso that no more than one of X^1 and X^2 is hydrogen;

when either X^1 or X^2 is $-(\text{CH}_2)_m-\text{N}(\text{R}^9)(\text{R}^{10})$, it is bonded to the carbon atom in the phenyl ring that is adjacent to the carbon atom in the phenyl ring to which $-\text{B}(\text{OH})_2$ is bonded, and the other of X^1 and X^2 is hydrogen.

2. The polymer of claim 1, comprising a repeat unit of Formula (I).
3. The polymer of claim 2, wherein the repeat unit of Formula (I) is selected from

the group consisting of



B(OH)₂ is at the 3- or 4- position of the ring.

4. A polymer comprising a repeat unit of Formula (Ia) to (If) according to claim 3, wherein,

R¹, R² and R³ are hydrogen;

A¹ and A² are independently absent or optionally substituted C₁-C₅ alkylene.


5. A polymer comprising a repeat unit of Formula (Ia) to (If) according to claim 3, wherein,

R¹ and R² are hydrogen;

R³ is methyl;


A¹ and A² are independently absent or optionally substituted C₁-C₅ alkylene.

6. The polymer of claim 1, comprising a repeat unit of Formula (II).
7. The polymer of claim 6, wherein in the repeat unit of Formula (II), Y^2 is direct bond;




and preferably the $-B(OH)_2$ is at the 3- or 4- position of the ring.






8. The polymer of claim 1, comprising a repeat unit of Formula (III).
9. The polymer of claim 8, wherein in the repeat unit of Formula (III), Y^2 is direct bond;




and preferably the $-B(OH)_2$ is at the 3- or 4- position of the ring.


10. A polymer comprising












b) at least one repeat unit selected from the group consisting of











where “n” represents an integer from 1 to 100,000.


11. A polymer selected from the group consisting of










12. A polymer selected from the group consisting of




13. A polymer selected from the group consisting of









14. A pharmaceutical composition comprising a polymer of any one of the preceding claims and a pharmaceutically acceptable excipient.

15. The pharmaceutical composition of claim 14, wherein the composition is a liquid, tablet, caplet or capsule.

16. The pharmaceutical composition of claim 14, wherein the composition is an enteric coated tablet, caplet or capsule.

17. The pharmaceutical composition of claim 16, wherein the enteric coated tablet, caplet or capsule is for targeted deliver to the duodenum.

18. A method for treating a metabolic disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer according to any one claims 1-13 or a pharmaceutical composition according to any one of claims 14-17.

19. The method of claim 18, further comprising administering another therapeutic agent to the subject in need thereof.

20. The method of claim 18 or claim 19, wherein the metabolic disorder is glucose intolerance, T1DM, T2DM, prediabetes, hyperlipidemia, obesity, overweight, dyslipidemia, hypertension, hyperglycemia, impaired glucose tolerance, insulin resistance, metabolic syndrome, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS).

21. The method of claim 18 or claim 19, wherein the metabolic disorder is type-2 diabetes mellitus.

22. A method for treating gastrointestinal disorder in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer according to any one claims 1-13 or a pharmaceutical composition according to any one of claims 14-17.